Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of -8.57% and -32.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Orchestra BioMed Holdings, Inc. Q2 Sales Decline
(RTTNews) - Orchestra BioMed Holdings, Inc. (OBIO) announced Loss for second quarter of -$24.079 million...
Nasdaq News: Markets
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +16.98% and -94.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +0.94% and +18.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +1.12% and -57.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Orchestra BioMed (OBIO) to Release Quarterly Earnings on Monday
Orchestra BioMed (NASDAQ:OBIO) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-orchestra-biomed-holdings-inc-stock...
MarketBeat
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of -55.00% and +3.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Sees Large Growth in Short Interest
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling...
MarketBeat
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat.com reports...
MarketBeat
Orchestra BioMed (OBIO) to Release Earnings on Wednesday
Orchestra BioMed (NASDAQ:OBIO) will be releasing its Q4 2025 earnings before the market opens on Wednesday, April 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-1-orchestra-biomed-holdings-inc-stock...
MarketBeat

Advertisement|Remove ads.